Lancet Respir Med: The impact of colchicine on the prognosis of COVID-19 patients

Colchicine has anti-inflammatory effects and has been proposed as a treatment drug for COVID-19
.

A study by Lancet Respir Med evaluated the efficacy and safety of colchicine in hospitalized patients with COVID-19

Colchicine has anti-inflammatory effects and has been proposed as a treatment for COVID-19

Randomized controlled studies were conducted in 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal to compare several possible treatments for COVID-19 inpatients with conventional treatments
.

Include patients with clinically suspected or confirmed new coronary pneumonia and have no medical history that faces major risks in participating in the trial

Randomized controlled studies were conducted in 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal to compare several possible treatments for COVID-19 inpatients with conventional treatments

From November 27, 2020 to March 4, 2021, of the 19,423 patients enrolled in the RECOVERY study included in the rehabilitation trial, 11,340 (58%) were eligible for colchicine treatment

The results show that colchicine does not reduce the 28-day mortality, length of hospital stay, or the risk of invasive mechanical ventilation or death in adult patients hospitalized with COVID-19
.

The results show that colchicine does not reduce the 28-day mortality, length of hospital stay, or the risk of invasive mechanical ventilation or death in adult patients hospitalized with COVID-19
.

Original source:

Original source:

Horby PW, Campbell M, Spata E, et al.

Horby PW, Campbell M, Spata E, et al.

Leave a message here